Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alumis Inc. ( (ALMS) ) has shared an update.
On September 3, 2025, Alumis Inc. updated its corporate presentation, highlighting its late-stage pipeline and upcoming milestones. The company anticipates significant data readouts in 2026 for its key programs, including Phase 3 results for psoriasis and Phase 2b results for systemic lupus erythematosus. These developments could potentially unlock substantial market opportunities and reinforce Alumis’s position in the precision immunology sector.
The most recent analyst rating on (ALMS) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Alumis Inc. stock, see the ALMS Stock Forecast page.
Spark’s Take on ALMS Stock
According to Spark, TipRanks’ AI Analyst, ALMS is a Neutral.
Alumis Inc. presents a challenging investment case primarily due to its poor financial performance, characterized by zero revenue, increasing losses, and negative cash flows. The technical analysis also indicates bearish trends, further weighing on the stock’s performance. Valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. However, the upcoming merger with ACELYRIN, Inc. offers a potential positive shift in the company’s prospects, providing financial stability and growth through an enhanced pipeline and financial resources.
To see Spark’s full report on ALMS stock, click here.
More about Alumis Inc.
Alumis Inc. operates in the precision immunology industry, focusing on developing innovative therapies for autoimmune and inflammatory diseases. The company has a robust pipeline that includes three clinical molecules targeting validated pathways, such as TYK2 inhibitors for conditions like psoriasis and systemic lupus erythematosus, and an anti-IGF-1R therapy for thyroid eye disease.
Average Trading Volume: 752,865
Technical Sentiment Signal: Hold
Current Market Cap: $482.9M
See more insights into ALMS stock on TipRanks’ Stock Analysis page.